By: Gervin-Hawkins H.B. No. 3785

A BILL TO BE ENTITLED

1	AN ACT
2	relating to labeling requirements for compounded drug products.
3	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
4	SECTION 1. Subchapter D, Chapter 562, Occupations Code, is
5	amended by adding Section 562.157 to read as follows:
6	Sec. 562.157. LABELING OF COMPOUNDED DRUG PRODUCTS. (a)
7	This section applies to:
8	(1) a pharmacy that compounds a sterile or non-sterile
9	preparation; and
10	(2) a manufacturer or other entity that compounds a
11	drug intended to be distributed:
12	(A) through a telepharmacy service;
13	(B) by over-the-counter sale; or
14	(C) directly from a pharmacist to a patient.
15	(b) A pharmacist may not furnish or dispense a compounded
16	drug to a patient unless the drug is labeled with the following
17	<pre>information:</pre>
18	(1) the patient's name;
19	(2) the name, address, telephone number, and license
20	<pre>number of:</pre>
21	(A) the pharmacy furnishing or dispensing the
22	compounded drug; or
23	(B) the pharmacy that prepared the compounded
24	drug, if that is not the same pharmacy described by Paragraph (A);

1	(3) the statement "Compounded Drug, Substitute for
2	(insert name of drug applicable to the compound)";
3	(4) all active ingredients used to prepare the
4	compounded drug;
5	(5) the compounded drug's beyond-use date, as
6	determined by the pharmacist using appropriate documented
7	<pre>criteria;</pre>
8	(6) the quantity or amount of the compounded drug in
9	the container dispensed to the patient;
10	(7) appropriate ancillary instructions, including:
11	(A) storage instructions; and
12	(B) cautionary instructions or statements,
13	including any hazardous drug warning;
14	(8) directions for use, including all appropriate:
15	(A) dosage directions; and
16	(B) other administration directions, including
17	as applicable, the appropriate dosage level per time interval;
18	(9) any side effects noted from trials, research, and
19	other appropriate information sources;
20	(10) whether the compounded drug was prepared in a
21	sterile facility or a non-sterile facility; and
22	(11) whether the compounded drug was prepared in a
23	location outside of the pharmacy that furnishes the drug to the
24	<pre>patient.</pre>
25	(c) The board shall adopt rules regarding the labeling
26	requirements of Subsection (b) in accordance with other existing
27	labeling requirements.

H.B. No. 3785

- 1 SECTION 2. Not later than December 1, 2025, the Texas State
- 2 Board of Pharmacy shall adopt the rules required by Section
- 3 562.157, Occupations Code, as added by this Act.
- 4 SECTION 3. This Act takes effect September 1, 2025.